Want to see LKFT full AI Analyst Report?
LKFT Stock Chart & Stats
$29.28
-$0.67(-2.33%)
At close: 4:00 PM EST
$29.28
-$0.67(-2.33%)
Day’s Range― - ―
52-Week Range$25.68 - $37.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)110.39K
Market Cap
$1.81B
Enterprise Value-$1.36K
Total Cash (Recent Filing)$2.98B
Total Debt (Recent Filing)$6.43M
Price to Earnings (P/E)3.2
Beta0.76
Next Earnings
Aug 10, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.42
Shares Outstanding65,897,070
10 Day Avg. Volume99,472
30 Day Avg. Volume110,389
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside-0.96% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$24.20M
Bulls Say, Bears Say
Bulls Say
Very Strong Balance Sheet And Cash ReservesNearly €3.0bn of cash and investments provides durable financial flexibility to fund clinical programs, execute strategic deals, and absorb operating losses without immediate dilution. This large liquidity buffer materially lowers short-to-medium term financing risk and preserves strategic optionality.
Ouro/Gilead Transaction Adds Clinical Asset And Strategic PartnerThe deal gives Lakefront a high-potential BCMAxCD3 asset with Fast Track/Orphan designations plus Gilead-led registrational/commercial paths. Joint development and royalty/profit-split mechanics de-risk commercialization, strengthen pipeline depth, and accelerate a capital-efficient route to market.
Improving Operating Metrics And R&D Cost DisciplineReduced R&D spend and cost control contributed to a marked improvement in operating loss, enhancing runway and capital efficiency. Sustained discipline can prolong the cash runway, allow prioritized trials, and reduce the need for near-term external funding or dilutive financing.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent cash burn despite reported accounting profits means operations do not generate sufficient cash. Over months this increases reliance on reserves or external capital, heightening execution risk for multi‑year development programs and reducing resilience to setbacks or delays.
Very Large Near-term Cash Outlays For Ouro And Wind-downConcentrated, one-time cash deployments materially draw down liquidity and force prioritization of programs. These outflows reduce headroom for discretionary investments, increase the consequences of execution slippage, and compress optionality for pursuing additional programs or acquisitions.
Sharp Revenue Volatility And Reliance On One-off OLCA RecognitionRevenue swung heavily due to timing of OLCA recognition, highlighting a weak recurring revenue base. This makes sustainable top-line forecasting harder, increases dependency on milestone/partner payments, and limits predictability of cash generation as programs transition through development.
Lakefront Biotherapeutics News
LKFT FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
Lakefront Biotherapeutics lowest stock price was $25.68 and its highest was $37.78 in the past 12 months.
What is Lakefront Biotherapeutics’s market cap?
Lakefront Biotherapeutics’s market cap is $1.81B.
When is Lakefront Biotherapeutics’s upcoming earnings report date?
Lakefront Biotherapeutics’s upcoming earnings report date is Aug 10, 2026 which is today.
How were Lakefront Biotherapeutics’s earnings last quarter?
Lakefront Biotherapeutics released its earnings results on May 06, 2026. The company reported $0.247 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $1.191.
Is Lakefront Biotherapeutics overvalued?
According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Overvalued.
Does Lakefront Biotherapeutics pay dividends?
Lakefront Biotherapeutics does not currently pay dividends.
What is Lakefront Biotherapeutics’s EPS estimate?
Lakefront Biotherapeutics’s EPS estimate is -0.82.
How many shares outstanding does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Lakefront Biotherapeutics reported an EPS of $0.247 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -3.749%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
Currently, no hedge funds are holding shares in LKFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lakefront Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.00 (-0.96% Downside)
$29.00 (-0.96% Downside)
Hedge Fund Trend
Decreased
By 32.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Lakefront Biotherapeutics
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
LKFT Company Deck
LKFT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.View all LKFT earnings summariesLKFT Stock 12 Month Forecast
Average Price Target
$29.00
▼(-0.96% Downside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
―
Insiders
1.70% Mutual Funds
25.58% Other Institutional Investors
72.01% Public Companies and
Individual Investors